SRSF2
SRSF2 (Serine/arginine-rich splicing factor 2) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Myeloproliferative neoplasms, Leukaemia, Myelodysplastic syndromes / neoplasms and 3 more.
Overview
Necessary for the splicing of pre-mRNA. It is required for formation of the earliest ATP-dependent splicing complex and interacts with spliceosomal components bound to both the 5'- and 3'-splice sites during spliceosome assembly. It also is required for ATP-dependent interactions of both U1 and U2 snRNPs with pre-mRNA.
CIViC holds 4 clinical evidence items and 0 assertions across 3 variants, naming CTX-712. Open Targets scores its association with cancer at 0.83 (direct and indirect evidence; datatypes literature 0.97, affected pathway 0.61, genetic association 0.79, somatic mutation 0.90). IntOGen calls it a driver in 1 cohort (1 activating, 0 loss-of-function), covering Acute Myeloid Leukaemia.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · SRSF2 (Serine/arginine-rich splicing factor 2) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Myeloproliferative neoplasms, Leukaemia, Myelodysplastic syndromes / neoplasms and 3 more.
- 1 · What it is
SRSF2 (Serine/arginine-rich splicing factor 2) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Myeloproliferative neoplasms, Leukaemia, Myelodysplastic syndromes / neoplasms and 3 more.
- 2 · What goes wrong in cancer
Necessary for the splicing of pre-mRNA. It is required for formation of the earliest ATP-dependent splicing complex and interacts with spliceosomal components bound to both the 5'- and 3'-splice sites during spliceosome assembly.
- 3 · How drugs use it
No product in this corpus aims at SRSF2 yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
External identifiers
Sources: HGNC HGNC:10783 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q01130 (protein name, function text, keywords and locations (REST API)); CIViC gene SRSF2 (4 evidence items, 0 assertions, 3 variants; diseases: Myeloid Neoplasm, Acute Myeloid Leukaemia, Myelodysplastic Syndrome (GraphQL API, CC0)); Open Targets ENSG00000161547 (association with cancer (MONDO_0004992) 0.83; per-cancer scores at or above 0.5: acute myeloid leukaemia 0.79, non-Hodgkin lymphoma 0.51, skin cancer 0.50, myelodysplastic syndrome 0.68, myeloproliferative neoplasm 0.83, leukaemia 0.83 (GraphQL API, CC0)); IntOGen SRSF2 (driver in 1 cohort (Act 1, LoF 0); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Necessary for the splicing of pre-mRNA. It is required for formation of the earliest ATP-dependent splicing complex and interacts with spliceosomal components bound to both the 5'- and 3'-splice sites during spliceosome assembly. It also is required for ATP-dependent interactions of both U1 and U2 snRNPs with pre-mRNA. Interacts with other spliceosomal components, via the RS domains, to form a bridge between the 5'- and 3'-splice site binding components, U1 snRNP and U2AF. Binds to purine-rich RNA sequences, either 5'-AGSAGAGTA-3' (S=C or G) or 5'-GTTCGAGTA-3'. Can bind to beta-globin mRNA and commit it to the splicing pathway. Location: Nucleus; Nucleus, nucleoplasm; Nucleus speckle (UniProt). Locus 17q25.2 (HGNC).
- Myeloproliferative neoplasms: Open Targets association 0.83 with myeloproliferative neoplasm (MONDO_0020076)
- Leukaemia: Open Targets association 0.83 with leukaemia (MONDO_0005059)
- Myelodysplastic syndromes / neoplasms: Open Targets association 0.68 with myelodysplastic syndrome (MONDO_0018881); CIViC evidence names this disease
- Non-Hodgkin lymphoma: Open Targets association 0.51 with non-Hodgkin lymphoma (MONDO_0018908)
- Skin cancer: Open Targets association 0.50 with skin cancer (MONDO_0002898)
- Acute myeloid leukaemia: Open Targets association 0.79 with acute myeloid leukaemia (MONDO_0018874); CIViC evidence names this disease
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 1 therapies; IntOGen calls it an activating (Act) driver in 1 cohort; CIViC holds 4 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
- Diseases the sources name that have no OnCo cancer page yet, so they are not linked: Myeloid Neoplasm.
Latest papers
topQuery for this target: (TITLE:"SRSF2" OR ABSTRACT:"SRSF2" OR TITLE:"serine and arginine rich splicing factor 2" OR ABSTRACT:"serine and arginine rich splicing factor 2" OR TITLE:"Serine/arginine-rich splicing factor 2" OR ABSTRACT:"Serine/arginine-rich splicing factor 2" OR TITLE:"SC-35" OR ABSTRACT:"SC-35" OR TITLE:"SC35" OR ABSTRACT:"SC35" OR TITLE:"PR264" OR ABSTRACT:"PR264") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about SRSF2, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetZRSR2
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types).
- TargetSF3B1
Shares RNA splicing, Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types).
- TargetGATA2
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Skin cancer (all types).
- TargetDDX41
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), CIViC.
- TargetGATA1
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Skin cancer (all types), CIViC.
- TargetSH2B3
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Non-Hodgkin lymphoma (all types).
- TargetU2AF1
Shares RNA splicing, Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types).
- TargetETV6
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Non-Hodgkin lymphoma (all types).